Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of type 2 diabetes mellitus prior to informed consent;~2. Male and female patients on diet and exercise regimen who are drug-naïve;~3. HbA1c \>= 7.0% and \<= 10.0% at Visit 1 (screening) for randomised treatment; HbA1c \> 10.0% at visit 1 (screening) for the open-label BI 10773 arm;~4. Age \>= 20 (Japan); Age \>= 18 (countries other than Japan);~5. BMI \<= 45 kg/m2 at Visit 1 (screening);~6. Signed and dated written informed consent by date of Visit 1~Exclusion criteria:~1. Uncontrolled hyperglycaemia;~2. Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or TIA within 3 months prior to informed consent;~3. Indication of liver disease, either ALT, AST, or alkaline phosphatase above 3 x ULN;~4. Impaired renal function (eGFR\<50 ml/min);~5. Bariatric surgery within the past two years or other GI surgeries;~6. Medical history of cancer;~7. Contraindications to sitagliptin;~8. Blood dyscrasias or any disorders causing haemolysis or unstable red blood cell;~9. Treatment with any anti-diabetes drug within 12 weeks prior to randomisation;~10. Treatment with anti-obesity drugs or any other treatment leading to unstable body weight;~11. Current treatment with systemic steroids or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except T2DM;~12. Pre-menopausal women who are nursing or pregnant or are of child-bearing potential and not practicing an acceptable method of birth control;~13. Alcohol or drug abuse;~14. Intake of an investigational drug in another trial within 30 days prior to intake of study medication in this trial;~15. Any other clinical condition that would jeopardize patients safety while participating in this clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI 10773 low dose (Type: EXPERIMENTAL): Patients receive BI 10773 low dose tablets once daily
- BI 10773 high dose (Type: EXPERIMENTAL): Patients receive BI 10773 high dose tablets once daily
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive tablets identical to those containing BI 10773 low dose and high dose and to Sitagliptin
- Sitagliptin 100 mg (Type: ACTIVE_COMPARATOR): Patients receive Sitagliptin 100 mg tablets once daily
- BI 10773 high dose open label (Type: EXPERIMENTAL): Patients receive BI 10773 high dose tablets open label once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).